| HTGC |
Hercules Capital, Inc. |
92%
|
Lexicon Pharmaceuticals, Inc. has entered into a loan facility with Hercules Capital, Inc. |
| HTGC |
Hercules Capital, Inc. |
92%
|
Reciprocal relationship from HTGC graph: Reciprocal relationship from LXRX graph: Lexicon Pharmaceuticals, Inc. has entered into a loan facility with Hercules Capital, Inc. |
| ARTAL-PARTICIPATIONS-S-R-L |
ARTAL-PARTICIPATIONS-S-R-L |
90%
|
On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| INVUS-ADVISORS-L-L-C |
INVUS-ADVISORS-L-L-C |
90%
|
On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| INVUS-ENTITIES |
INVUS-ENTITIES |
90%
|
On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| INVUS-GLOBAL-MANAGEMENT-LLC |
INVUS-GLOBAL-MANAGEMENT-LLC |
90%
|
On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| INVUS-L-P |
INVUS-L-P |
90%
|
On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| INVUS-PUBLIC-EQUITIES-ADVISORS-LLC |
INVUS-PUBLIC-EQUITIES-ADVISORS-LLC |
90%
|
On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| INVUS-PUBLIC-EQUITIES-L-P |
INVUS-PUBLIC-EQUITIES-L-P |
90%
|
On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| INVUS-US-PARTNERS-LLC |
INVUS-US-PARTNERS-LLC |
90%
|
On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| NOVO-NORDISK |
NOVO-NORDISK |
90%
|
LX9851 is a first-in-class, non-incretin, oral, small molecule inhibitor of acyl-CoA synthetase 5 (ACSL5) in development by Novo Nordisk for obesity and associated metabolic disorders |
| OXFORD-FINANCE |
OXFORD-FINANCE |
90%
|
The initial $55 million tranche was funded at closing and will be used to repay Lexicon’s existing loan facility with Oxford Finance. |
| PREFERRED-PRIVATE-PLACEMENT-PURCHASER |
PREFERRED-PRIVATE-PLACEMENT-PURCHASER |
90%
|
Additionally, on January 29, 2026, the Company entered into a Preferred Stock Purchase Agreement with an affiliate of Invus (the “ Preferred Private Placement Purchaser ” and, such agreement, the “ P… |
| RAYMOND-DEBBANE |
RAYMOND-DEBBANE |
90%
|
On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| SIREN-LLC |
SIREN-LLC |
90%
|
On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| ULYS-L-L-C |
ULYS-L-L-C |
90%
|
On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| OXFORD-TERM-LOANS |
OXFORD-TERM-LOANS |
80%
|
As of March 31, 2026, we are subject to interest rate sensitivity on our outstanding Oxford Term Loans which bear interest at a floating rate equal to the 1-month CME Term SOFR rate. |
| STENO-DIABETES-CENTER |
STENO-DIABETES-CENTER |
80%
|
STENO1, a third-party funded, investigator-initiated study of sotagliflozin being conducted by the STENO Diabetes Center (Denmark) |
